Research in Extracorporeal Life Support: A Call to Action

Daniel Brodie; Jean-Louise Vincent; Laurent J. Brochard; Alain Combes; Niall D. Ferguson; Carol L Hodgson; John G Laffey; Alain Mercat; Antonio Pesenti; Michael Quintel; Arthur S Slutsky; V. Marco Ranieri; on behalf of the International ECMO Network (EMCONet)

doi:10.1016/j.chest.2017.12.024

Research in Extracorporeal Life Support: A Call to Action

Daniel Brodie, Jean-Louise Vincent, Laurent J. Brochard, Alain Combes, Niall D. Ferguson, Carol L Hodgson, John G Laffey, Alain Mercat, Antonio Pesenti, Michael Quintel, Arthur S Slutsky, V. Marco Ranieri, on behalf of the International ECMO Network (EMCONet)

Acute & Critical Care

Research output: Contribution to journal › Comment / Debate › Other › peer-review

15 Citations (Scopus)

Abstract

Extracorporeal life support (ECLS) refers to a group of techniques that provide extracorporeal gas exchange or circulatory support for patients with respiratory or cardiac failure. The use of ECLS in adults has grown exponentially in the last decade,1,2 fueled both by technological advances in cardiopulmonary bypass equipment, from which ECLS was principally derived, and by several specific events. The perceived need for advanced respiratory support in patients with influenza A(H1N1)-associated ARDS during the 2009 pandemic,3 along with the publication of the Conventional Ventilation or ECMO for Severe Adult Respiratory Failure (CESAR) trial that same year,4 generated considerable interest in ECLS for
adult respiratory failure.5 Although use of cardiac ECLS was already growing, its use increased dramatically in some countries
after the publication of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial.2,6 The current growth of ECLS is outpacing the evidence base supporting its use.7-9 For example, in the last decade, only one large randomized clinical trial assessing the efficacy of ECLS for respiratory failure has been published; none has been published for cardiac failure.
This lack of data leaves us without definitive answers to a number of important questions, including the most fundamental: When is
ECLS indicated? Also, is it superior to the best current standard of care?

Original language	English
Pages (from-to)	788-791
Number of pages	4
Journal	Chest
Volume	153
Issue number	4
DOIs	https://doi.org/10.1016/j.chest.2017.12.024
Publication status	Published - 1 Apr 2018

Keywords

ECLS
evidence
extracorporeal life support
research networks

Access to Document

10.1016/j.chest.2017.12.024

239026989Final published version, 148 KB

Link to publication in Scopus

Cite this

Brodie, Daniel ; Vincent, Jean-Louise ; Brochard, Laurent J. ; Combes, Alain ; Ferguson, Niall D. ; Hodgson, Carol L ; Laffey, John G ; Mercat, Alain ; Pesenti, Antonio ; Quintel, Michael ; Slutsky, Arthur S ; Ranieri, V. Marco ; on behalf of the International ECMO Network (EMCONet). / Research in Extracorporeal Life Support : A Call to Action. In: Chest. 2018 ; Vol. 153, No. 4. pp. 788-791.

@article{64768a6ee50f48519a308dd5d3ec4778,

title = "Research in Extracorporeal Life Support: A Call to Action",

abstract = "Extracorporeal life support (ECLS) refers to a group of techniques that provide extracorporeal gas exchange or circulatory support for patients with respiratory or cardiac failure. The use of ECLS in adults has grown exponentially in the last decade,1,2 fueled both by technological advances in cardiopulmonary bypass equipment, from which ECLS was principally derived, and by several specific events. The perceived need for advanced respiratory support in patients with influenza A(H1N1)-associated ARDS during the 2009 pandemic,3 along with the publication of the Conventional Ventilation or ECMO for Severe Adult Respiratory Failure (CESAR) trial that same year,4 generated considerable interest in ECLS foradult respiratory failure.5 Although use of cardiac ECLS was already growing, its use increased dramatically in some countriesafter the publication of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial.2,6 The current growth of ECLS is outpacing the evidence base supporting its use.7-9 For example, in the last decade, only one large randomized clinical trial assessing the efficacy of ECLS for respiratory failure has been published; none has been published for cardiac failure.This lack of data leaves us without definitive answers to a number of important questions, including the most fundamental: When isECLS indicated? Also, is it superior to the best current standard of care? ",

keywords = "ECLS, evidence, extracorporeal life support, research networks",

author = "Daniel Brodie and Jean-Louise Vincent and Brochard, {Laurent J.} and Alain Combes and Ferguson, {Niall D.} and Hodgson, {Carol L} and Laffey, {John G} and Alain Mercat and Antonio Pesenti and Michael Quintel and Slutsky, {Arthur S} and Ranieri, {V. Marco} and {on behalf of the International ECMO Network (EMCONet)}",

year = "2018",

month = apr,

day = "1",

doi = "10.1016/j.chest.2017.12.024",

language = "English",

volume = "153",

pages = "788--791",

journal = "Chest",

issn = "0012-3692",

publisher = "American College of Chest Physicians",

number = "4",

}

Research in Extracorporeal Life Support : A Call to Action. / Brodie, Daniel; Vincent, Jean-Louise; Brochard, Laurent J.; Combes, Alain; Ferguson, Niall D.; Hodgson, Carol L; Laffey, John G; Mercat, Alain; Pesenti, Antonio; Quintel, Michael; Slutsky, Arthur S; Ranieri, V. Marco; on behalf of the International ECMO Network (EMCONet).

In: Chest, Vol. 153, No. 4, 01.04.2018, p. 788-791.

Research output: Contribution to journal › Comment / Debate › Other › peer-review

TY - JOUR

T1 - Research in Extracorporeal Life Support

T2 - A Call to Action

AU - Brodie, Daniel

AU - Vincent, Jean-Louise

AU - Brochard, Laurent J.

AU - Combes, Alain

AU - Ferguson, Niall D.

AU - Hodgson, Carol L

AU - Laffey, John G

AU - Mercat, Alain

AU - Pesenti, Antonio

AU - Quintel, Michael

AU - Slutsky, Arthur S

AU - Ranieri, V. Marco

AU - on behalf of the International ECMO Network (EMCONet)

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Extracorporeal life support (ECLS) refers to a group of techniques that provide extracorporeal gas exchange or circulatory support for patients with respiratory or cardiac failure. The use of ECLS in adults has grown exponentially in the last decade,1,2 fueled both by technological advances in cardiopulmonary bypass equipment, from which ECLS was principally derived, and by several specific events. The perceived need for advanced respiratory support in patients with influenza A(H1N1)-associated ARDS during the 2009 pandemic,3 along with the publication of the Conventional Ventilation or ECMO for Severe Adult Respiratory Failure (CESAR) trial that same year,4 generated considerable interest in ECLS foradult respiratory failure.5 Although use of cardiac ECLS was already growing, its use increased dramatically in some countriesafter the publication of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial.2,6 The current growth of ECLS is outpacing the evidence base supporting its use.7-9 For example, in the last decade, only one large randomized clinical trial assessing the efficacy of ECLS for respiratory failure has been published; none has been published for cardiac failure.This lack of data leaves us without definitive answers to a number of important questions, including the most fundamental: When isECLS indicated? Also, is it superior to the best current standard of care?

AB - Extracorporeal life support (ECLS) refers to a group of techniques that provide extracorporeal gas exchange or circulatory support for patients with respiratory or cardiac failure. The use of ECLS in adults has grown exponentially in the last decade,1,2 fueled both by technological advances in cardiopulmonary bypass equipment, from which ECLS was principally derived, and by several specific events. The perceived need for advanced respiratory support in patients with influenza A(H1N1)-associated ARDS during the 2009 pandemic,3 along with the publication of the Conventional Ventilation or ECMO for Severe Adult Respiratory Failure (CESAR) trial that same year,4 generated considerable interest in ECLS foradult respiratory failure.5 Although use of cardiac ECLS was already growing, its use increased dramatically in some countriesafter the publication of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial.2,6 The current growth of ECLS is outpacing the evidence base supporting its use.7-9 For example, in the last decade, only one large randomized clinical trial assessing the efficacy of ECLS for respiratory failure has been published; none has been published for cardiac failure.This lack of data leaves us without definitive answers to a number of important questions, including the most fundamental: When isECLS indicated? Also, is it superior to the best current standard of care?

KW - ECLS

KW - evidence

KW - extracorporeal life support

KW - research networks

UR - http://www.scopus.com/inward/record.url?scp=85044099667&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2017.12.024

DO - 10.1016/j.chest.2017.12.024

M3 - Comment / Debate

AN - SCOPUS:85044099667

VL - 153

SP - 788

EP - 791

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4

ER -